Chronic back pain — defined as pain persisting for more than three months — is one of the most prevalent causes of disability in the UK and one of the most common presenting complaints at private cannabis clinics. It is important to understand from the outset that acute back pain does not qualify; the prescribing framework for cannabis-based medicines in pain conditions requires documented chronicity, evidence of treatment failure, and significant functional impairment. Patients with acute back pain should follow NICE NG59 guidance, which recommends self-management, physiotherapy, and short courses of NSAIDs.

Chronic vs Acute Back Pain: Only Chronic Qualifies

The three-month threshold for chronicity is not arbitrary. Acute low back pain resolves in the majority of patients within six to twelve weeks with appropriate conservative management. Chronic back pain represents a distinct clinical entity, often involving central sensitisation — a state of heightened neural excitability that amplifies pain signals — in addition to peripheral nociceptive input from damaged or degenerate structures. Central sensitisation explains why chronic back pain frequently does not respond to the same treatments that are effective in acute pain, and why it may respond to agents that modulate central pain processing.

Nociceptive vs Neuropathic Components

Chronic back pain is frequently mixed in nature: it may have both nociceptive components (arising from damaged discs, facet joints, or paraspinal muscles) and neuropathic components (arising from nerve root compression or injury). Sciatica — characterised by radiating pain down the leg in the distribution of the sciatic nerve — is the classic presentation of neuropathic back pain. The distinction matters because neuropathic pain tends to respond better to certain agents (gabapentinoids, TCAs, SNRIs) and because neuropathic pain is one of the better-evidenced indications for cannabis-based medicines in the UK.

Patients with chronic back pain that has a clearly neuropathic character — shooting, burning, or electric-shock quality pain radiating into the limbs, with or without sensory changes — may be assessed under a neuropathic pain indication. Patients with predominately nociceptive chronic pain may be assessed under a general chronic pain indication. Both pathways are available.

The Endocannabinoid System and Spinal Pain

CB1 receptors are densely expressed in spinal cord regions involved in pain processing, including the dorsal horn — the primary spinal relay point for ascending pain signals. CB1 receptor activation inhibits the release of excitatory neurotransmitters at synaptic terminals in the dorsal horn, reducing the transmission of pain signals to the brain. This spinal mechanism is distinct from, and additive with, supra-spinal pain modulation by cannabinoids.

CB2 receptors are expressed on spinal microglia and in peripheral nerve tissue, and activation can reduce neuroinflammatory signalling that contributes to central sensitisation. THC acts primarily at CB1 receptors, with well-documented analgesic effects. CBD does not act directly at CB1 receptors but modulates the endocannabinoid system indirectly, has anti-inflammatory properties, and may reduce the anxiety and sleep disruption that are common comorbidities in chronic back pain patients.

Evidence Base for Cannabis in Chronic Back Pain

The evidence for cannabis-based medicines in chronic pain generally is among the strongest in the cannabis medicine literature. Systematic reviews consistently find that cannabis-based medicines provide meaningful reductions in chronic pain intensity and improvements in quality of life. The NICE evidence review on cannabis-based medicines (2019) and subsequent updates acknowledge moderate-quality evidence for cannabis in chronic pain, including neuropathic pain.

Evidence specifically for back pain as a subset of chronic pain is less robust in terms of dedicated randomised controlled trials, but back pain is consistently one of the most common presenting conditions in real-world cannabis medicine datasets. A 2020 study using the UK Medical Cannabis Registry found that chronic pain patients — of whom back pain was a leading diagnosis — showed significant improvements in pain-related outcomes including the Brief Pain Inventory and EQ-5D quality of life measures at six and twelve months.

First-Line Therapies Before Cannabis: NICE NG193

NICE Guideline NG193 (Chronic Primary Pain) and NICE NG59 (Low Back Pain) provide the framework for conventional management. Before a cannabis prescription is appropriate, patients are expected to have engaged with: physiotherapy and structured exercise programmes; non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen; where neuropathic components are present, gabapentinoids (pregabalin, gabapentin), SNRIs (duloxetine), or TCAs (amitriptyline); pain psychology including acceptance and commitment therapy or pain management programmes. Opioids have a limited evidence base in chronic non-cancer pain and are associated with significant risks; NICE NG193 recommends against their use for chronic primary pain. A history of inadequate opioid response, or avoidance of opioids due to risk factors, is a relevant part of the clinical picture for cannabis assessment.

Who Qualifies and How to Access an Assessment

Patients most likely to be considered appropriate for a cannabis prescription for chronic back pain are those with: a diagnosis of chronic low back pain, sciatica, or spinal pain documented for more than three months; evidence of inadequate response to or intolerance of physiotherapy, NSAIDs, and relevant prescription analgesics; significant functional impairment — difficulty with daily activities, sleep disruption, or inability to work — attributable to the pain; a specialist assessment confirming appropriateness. Imaging findings (disc degeneration, herniation, facet arthropathy) are not required but are useful supporting information. A GP referral to a private cannabis clinic is not required. See UK medical cannabis clinics and how to get a medical cannabis prescription in the UK for further information.

Frequently Asked Questions

Can I get a medical cannabis prescription for back pain in the UK?

Yes, if your back pain is chronic (persisting for more than three months) and has not responded adequately to conventional treatments including physiotherapy, NSAIDs, and appropriate prescription medications. Medical cannabis is not prescribed for acute back pain. A GMC-registered specialist will assess your full clinical history, including your treatment record, before making a prescribing decision.

Does sciatica qualify as a separate condition for medical cannabis prescribing?

Sciatica with a persistent neuropathic character — radiating pain, burning, shooting, or sensory changes in the leg — would typically be assessed under a neuropathic pain indication, which has good evidence support in the UK cannabis prescribing framework. Pure nociceptive back pain without neuropathic features would be assessed under a chronic pain indication. Both are valid pathways.

I have tried physiotherapy and anti-inflammatories but they have not helped enough. Am I eligible?

Documented inadequate response to physiotherapy and NSAIDs is a positive factor in your eligibility assessment. Specialists will also want to see whether prescription-level analgesics — gabapentinoids, duloxetine, or TCAs for neuropathic components — have been tried. The more complete your treatment history, and the more clearly documented it is, the stronger your case for a specialist assessment is.

Will medical cannabis remove my back pain entirely?

Medical cannabis is unlikely to eliminate chronic back pain entirely. Clinical evidence shows meaningful reductions in pain intensity and improvements in quality of life, but complete resolution is not a realistic expectation for most patients with chronic musculoskeletal or neuropathic pain. The realistic goals are reduction in pain intensity, improvement in functional capacity, better sleep, and reduced reliance on other analgesics.

Can I drive while taking prescribed medical cannabis for back pain?

Prescribed cannabis-based medicines containing THC can impair driving, and it is illegal to drive with THC above the specified limit in the blood under UK drug-driving law, regardless of whether it is prescribed. Patients prescribed THC-containing medicines should not drive until they and their specialist are satisfied that their reaction time, concentration, and coordination are not impaired. Discuss driving with your prescribing specialist before starting treatment.